Amaranth Medical

Amaranth Medical is a biotechnology startup with a mission to revolutionize interventional cardiology through the development of fully bioresorbable, versatile scaffolds with exceptional mechanical properties. The company, founded in 2005, aims to set a new global standard of care for stent interventions. Amaranth Medical is named after the Greek word for "never fading," symbolizing its commitment to providing enduring clinical benefits with its scaffold solutions, which continue to support patient health long after the polymeric device has resorbed. The company's most recent funding round was a $20.00M Series B investment led by EDBI, Charter Life Sciences, and PhillipCapital on 08 October 2013. With a strong focus on the biotechnology and health care industries, Amaranth Medical is poised to make a lasting clinical impact on a global scale.